Show simple item record

dc.contributor.authorMansoor, Was
dc.contributor.authorKulkarni, A. S.
dc.contributor.authorKato, K.
dc.contributor.authorSun, J. M.
dc.contributor.authorShah, M. A.
dc.contributor.authorEnzinger, P. C.
dc.contributor.authorAdenis, A.
dc.contributor.authorDoi, T.
dc.contributor.authorKojima, T.
dc.contributor.authorMetges, J. P.
dc.contributor.authorLi, Z. G.
dc.contributor.authorKim, S. B.
dc.contributor.authorCho, B. C.
dc.contributor.authorSunpaweravong, P.
dc.contributor.authorAlsina, M.
dc.contributor.authorGoekkurt, E.
dc.contributor.authorSuryawanshi, S.
dc.contributor.authorNorquist, J.
dc.contributor.authorShah, S.
dc.contributor.authorShen, L.
dc.date.accessioned2021-05-18T08:48:03Z
dc.date.available2021-05-18T08:48:03Z
dc.date.issued2021en
dc.identifier.citationMansoor W, Kulkarni AS, Kato K, Sun J-M, Shah MA, Enzinger PC, et al. Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study. JCO. 2021 Jan 20;39(3_suppl):168–168.en
dc.identifier.doi10.1200/JCO.2021.39.3_suppl.168en
dc.identifier.urihttp://hdl.handle.net/10541/623994
dc.description.abstractBackground: In the randomized, international, double-blind, placebo-controlled KEYNOTE-590 (NCT03189719) study, pembrolizumab (pembro) + chemotherapy (chemo) provided statistically significant and clinically meaningful improvement in OS, PFS, and ORR vs placebo + chemo as first-line therapy for patients (pts) with locally advanced/unresectable or metastatic adenocarcinoma or esophageal squamous cell carcinoma (ESCC) or Siewert type 1 esophagogastric junction adenocarcinoma (EGJ). Here we report HRQoL outcomes in KEYNOTE-590. Methods: 749 pts were randomized 1:1 to pembro 200 mg or placebo Q3W for up to 2y + chemo (cisplatin 80 mg/m2 Q3W [d1; 6 doses] + 5-FU 800 mg/m2 on d1-5 Q3W). EORTC QLQ-C30, EORTC QLQ-OES18, and EQ-5D-5L questionnaires were administered at baseline, every 3 weeks (Q3W) up to week 24, and then Q9W up to 1 year or end of treatment, and at the 30-d safety follow-up visit. HRQoL was assessed in all treated patients who completed ≥1 HRQoL assessment (N = 711: 356 for pembro + chemo; 355 for chemo). Change from baseline to week 18 in EORTC-QLQ-C30 global health status (GHS)/QoL and physical functioning, and in QLQ-OES18 scores were prespecified secondary endpoints. Change from baseline to week 18 in EQ-5D scores was an exploratory endpoint. Time to deterioration (TTD) was evaluated for all endpoints. Least square mean (LSM) change from baseline (95% CI) was compared using a constrained longitudinal data analysis model. TTD was compared using a stratified log rank test and Cox proportional hazards model. P-values are nominal and two-sided. Results: QLQ-C30, QLQ-OES18 and EQ-5D-5L compliance was ≥90% in both arms at baseline and at week 18. There was no significant difference in least squares mean (LSM) change from baseline to week 18 in GHS/QoL status between arms (LSM difference [95% CI] -0.10 [-3.40-3.20]; P = 0.9530). Median TTD in GHS/QoL was similar between arms (HR, 0.86 [95% CI, 0.66-1.13]; P = 0.2864). Outcomes were similar in ESCC PD-L1 CPS ≥10, ESCC, and PD-L1 CPS ≥10 patient populations. LSM change from baseline to week 18 for QLQ-OES18 pain subscale was better for pembro + chemo (-4.78) vs chemo (-1.85 ) (-2.94, -5.86 to -0.02; P = 0.0487). There was no significant difference in LSM change from baseline to week 18 between arms for reflux (-1.19; -4.49-2.10; P = 0.4781) or dysphagia (-2.35; -7.78-3.07; P = 0.3945). VAS LSM change from baseline to week 18 was similar between arms (1.20, -1.61-4.01; P = 0.4016). Conclusions: HRQoL was stable and similar over 18 weeks in the pembro + chemo and chemo arms. Together with superior OS, PFS, and ORR and a manageable safety profile with pembro + chemo, these results support the clinically meaningful benefit of pembro + chemo in patients with advanced esophageal cancer including EGJ adenocarcinomaen
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2021.39.3_suppl.168en
dc.titleHealth-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, United Kingdomen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen


This item appears in the following Collection(s)

Show simple item record